Skip to main content
. 2015 Jun 10;35(23):8691–8700. doi: 10.1523/JNEUROSCI.0417-15.2015

Figure 3.

Figure 3.

Candidate SMA therapeutics and their progress through the clinical development pipeline. The chart summarizes the current status of the most advanced programs in SMA therapeutic development based on publicly available information. Small molecules and biologics listed with blue bars aim to increase the functional levels of SMN, and those denoted with red bars act by improving motor system function through SMN-independent mechanisms.